checkAd

Advicenne Announces Its Financial Calendar For 2023

Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, releases its financial Calendar for 2023.

Event

Date*

2022 Full-year financial results

March 30, 2023 after market close

Annual General Meeting

June 8, 2023

2023 H1 financial results

September 21, 2023 after market close

 

*: may be modified.

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information see: https://advicenne.com/.

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets, and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.


The Advicenne Stock currently trades with a fall of -0,75 % to 3,648EUR on the Lang & Schwarz stock exchange.

Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  105   |   |   

Schreibe Deinen Kommentar

Disclaimer

Advicenne Announces Its Financial Calendar For 2023 Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, releases its financial …

Nachrichten des Autors

276 Leser
232 Leser
192 Leser
188 Leser
184 Leser
1680 Leser
764 Leser
564 Leser
536 Leser
440 Leser
3236 Leser
2100 Leser
1920 Leser
1680 Leser
1604 Leser
7528 Leser
3236 Leser
3061 Leser
2934 Leser
2493 Leser